<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>MULTITRACE-4 NEONATAL- zinc sulfate heptahydrate, cupric sulfate, manganese sulfate and chromic chloride injection, solution </strong><br>American Regent, Inc.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>
<span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold">-4 NEONATAL (TRACE ELEMENTS INJECTION 4, USP)</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_56efe9a7-747c-4ea3-8c89-83b89bbfe419"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">FOR IV USE AFTER DILUTION</p>
<p><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_09f64fe5-7bbd-4c64-bd2b-bbfd8e0feb9b"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION </span></h1>
<p class="First"><span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 NEONATAL (TRACE ELEMENTS INJECTION 4, USP) </span>is a sterile, nonpyrogenic solution containing four trace elements for use as an additive for Total Parenteral Nutrition (TPN).</p>
<p><span class="Bold">Each mL provides:</span></p>
<p>Zinc                                                                                                     1.5 mg<br>Copper                                                                                                 0.1 mg<br>Manganese                                                                                          25 mcg<br>Chromium                                                                                           0.85 mcg</p>
<p><span class="Bold">Each mL contains:</span></p>
<p>Zinc Sulfate (Heptahydrate)                                                               6.6 mg<br>Cupric Sulfate (Pentahydrate)                                                          0.39 mg<br>Manganese Sulfate (Monohydrate)                                                     77 mcg<br>Chromic Chloride (Hexahydrate)                                                       4.36 mcg<br>Water for Injection                                                                              q.s</p>
<p>pH (range 2.3-2.7) may be adjusted with Sulfuric Acid and/or Sodium Hydroxide.</p>
<p>Zinc Sulfate is chemically designated ZnSO<span class="Sub">4</span>, a white crystalline compound freely soluble in water. Cupric Sulfate is chemically designated CuSO<span class="Sub">4</span>, a blue crystalline compound very soluble in water. Manganese Sulfate is chemically designated MnSO<span class="Sub">4</span>, a <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> red, slightly efflorescent compound soluble in water. Chromic Chloride is chemically designated CrCl<span class="Sub">3</span>, a greenish compound, soluble in water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_76e18477-1e11-487c-a076-52e7a61f9f33"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY
</span></h1>
<p class="First"><span class="Bold">ZINC </span>is an essential nutritional requirement that serves as a cofactor for more than 70 different enzymes including carbonic anhydrase, alkaline phosphatase, lactic dehydrogenase, and both RNA and DNA polymerase. Zinc facilitates <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, helps maintain normal skin hydration, and senses of taste and smell.</p>
<p>Zinc resides in muscle, bone, skin, kidney, liver, pancreas, retina, prostate, and particularly in the red and white blood cells. Zinc binds plasma albumin α<span class="Sub">2</span>-macroglobulin, and some plasma amino acids including histidine, cysteine, threonine, glycine, and asparagine. Ingested zinc is excreted mainly in the stool (approximately 90%), and to a lesser extent in the urine and in perspiration. Providing zinc during TPN prevents development of the following deficiency symptoms: Parakeratosis, <span class="product-label-link" type="condition" conceptid="44783805" conceptname="Hypogeusia">hypogeusia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">dysosmia</span>, geophagia, <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>, <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> and <span class="product-label-link" type="condition" conceptid="4279681" conceptname="Hepatosplenomegaly">hepatosplenomegaly</span>.</p>
<p>The initial manifestations of hypozincemia in TPN patients are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. At plasma levels below 20 mcg zinc/100 mL, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> followed by <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> has been reported for TPN patients. Normal zinc plasma levels are 100 ± 12 mcg/100 mL.</p>
<p><span class="Bold">COPPER </span>is an essential nutrient that serves as a cofactor for serum <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>, an oxidase necessary for proper formation of the iron carrier protein, transferrin. Providing copper during TPN helps prevent development of the following deficiency symptoms: <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, depressed <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span> levels, impaired transferrin formation and secondary <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span>.</p>
<p>Normal serum copper values range from 80 to 163 mcg/100 mL (mean, approximately 110 mcg/100 mL). The serum copper level at which deficiency symptoms appear is not precisely defined. The daily turnover of copper through <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span> is approximately 0.5 mg. Excretion of copper is through the bile (80%), directly through the intestinal wall (16%), and in urine (4%).</p>
<p><span class="Bold">MANGANESE </span>is an essential nutrient that serves as an activator for enzymes such as polysaccharide polymerase, liver arginase, <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span>, and <span class="product-label-link" type="condition" conceptid="4029769" conceptname="Pyruvic acid">pyruvate</span> carboxylase.</p>
<p>Providing manganese during TPN prevents development of the following deficiency symptoms: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, and changes in growth and color of hair. Under conditions of minimal intake, 20 mcg manganese/day is retained. Manganese is bound to a specific transport protein, transmanganin, a β<span class="Sub">1</span>-globulin. Manganese is widely distributed but concentrates in the mitochondria-rich tissues such as brain, kidney, pancreas, and liver. Assay for manganese in whole blood results in concentrations ranging from 6 to 12 mcg manganese/liter. Excretion of manganese occurs mainly through the bile, but in the event of obstruction, ancillary excretion routes include pancreatic juice, or return to the lumen of duodenum, jejunum, or ileum. Urinary excretion of manganese is negligible.</p>
<p>Trivalent <span class="Bold">CHROMIUM </span>is part of glucose tolerance factor, an activator of insulin-mediated reactions. Chromium helps to maintain normal glucose metabolism and peripheral nerve function. Providing chromium during TPN prevents development of the following deficiency symptoms: impaired glucose tolerance, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, and a <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span> similar to mild/moderate <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>.</p>
<p>Serum chromium is bound to transferrin (siderophilin) in the β-globulin fraction. Typical blood levels for chromium range from 1 to 5 mcg/liter, but blood levels are not considered a meaningful index of tissue stores. Administration of chromium supplements to chromium-deficient patients can result in normalization of the glucose tolerance curve from the diabetic-like curve typical of chromium deficiency. This response is viewed as a more meaningful indicator of chromium nutriture than serum chromium levels.</p>
<p>Excretion of chromium is via the kidneys, ranging from 3 to 50 mcg/day. Biliary excretion via the small intestine may be an ancillary route, but it is believed that only small amounts of chromium are excreted in this matter.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_513d6add-0ae4-42f4-a546-57983b45568d"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE
</span></h1>
<p class="First"><span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 NEONATAL </span>is indicated for use as a supplement to intravenous solutions given for TPN. Administration of <span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 NEONATAL </span>in TPN solutions helps to maintain plasma levels of zinc, copper, manganese, and chromium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_a4fefbc1-aaa6-4d33-a7c4-83fa9c7e55e6"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS
</span></h1>
<p class="First"><span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 NEONATAL </span>should not be given undiluted by direct injection into a peripheral vein because of the potential of infusion <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_83ff2715-62ba-456f-9ac8-e1b747bd4de9"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS
</span></h1>
<p class="First"><span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 NEONATAL is a hypotonic solution which should be administered in admixtures only. Supplementation of TPN solutions with Neonatal Formula should be immediately discontinued if toxicity symptoms due to any of the constituent trace elements in Neonatal Formula is observed in the patient.</span></p>
<p><span class="Bold">This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.</span></p>
<p><span class="Bold">Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_2bd6c21b-422a-4d6a-a8e6-497474b1e097"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS
</span></h1>
<p class="First">1.	Before administering <span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 NEONATAL </span>in TPN solutions, the 	physician must assess the metabolic requirements of trace elements and disease 	state of the patient. Frequent determinations of serum levels of the four trace 	elements are suggested as a guideline for adjusting the dosage or completely 	omitting <span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 NEONATAL</span>. ZINC is eliminated via the intestine 	and kidneys; COPPER and MANGANESE are eliminated via the bile; and 	CHROMIUM primarily via the kidneys. The possibility of their retention should be 	considered in patients with malfunctioning excretory routes of the 	respective trace 	elements.</p>
<p>2. 	Syringes equipped with aluminum needles or hubs should not be used, as the 	solution is acidic.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_529ac4fe-9941-4e6b-9eb7-0ba921f87093"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold"><span class="Italics">Pregnancy
</span></span></h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_ad5963c3-7839-41a6-814b-07691b82be26"></a><a name="section-7.1.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects
</span></h3>
<p class="First">Pregnancy Category C: Animal reproduction studies have not been conducted with <span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 NEONATAL</span>. It is also not known whether Neonatal Formula can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Neonatal Formula should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_458d7565-8666-4d6a-9cbf-56d028db6aa5"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS
</span></h1>
<p class="First">The amounts of <span class="Bold">ZINC, COPPER, MANGANESE, </span>and <span class="Bold">CHROMIUM </span>in <span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 NEONATAL </span>are very small and toxicity symptoms due to these trace elements at suggested dosage levels are considered unlikely to occur.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_8bc411d0-bf28-4534-9798-cccdc1f0041e"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">OVERDOSAGE
</span></h1>
<p class="First">Single intravenous doses of 1 to 2 mg zinc/kg body weight have been given to adult <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> patients without toxic manifestations. However, acute toxicity was reported in an adult when 10 mg zinc was infused over a period of one hour on each of four consecutive days. Profuse <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, decreased level of consciousness, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> (140/min.), and marked <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> (94.2ºF) on the fourth day were accompanied by a serum zinc concentration of 207 mcg/mL. Symptoms abated within three hours. Hyperamylasemia may be a sign of impending zinc overdosage; patients receiving an inadvertent <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (25 mg zinc/liter of TPN solution, equivalent to 50 to 70 mg zinc/day) developed hyperamylasemia (557 to 1850 Klein units; normal: 130-310).</p>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> resulted from an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in which 1683 mg zinc was delivered intravenously over the course of 60 hours to a 72 year old patient. Symptoms of <span class="Bold">ZINC </span>toxicity included <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (80/40 mm Hg), <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, and <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, with a serum zinc level of 4184 mcg/100 mL. Calcium supplements may confer a protective effect against zinc toxicity.</p>
<p><span class="Bold">COPPER </span>toxicity can produce <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">prostration</span>, behavior change, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, progressive marasmus, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>. Such symptoms have been reported with a serum copper level of 286 mcg/100 mL. D-penicillamine has been reported effective as an antidote.</p>
<p><span class="Bold">MANGANESE </span>toxicity in TPN patients has not been reported within the prescribed dosage.</p>
<p>Trivalent <span class="Bold">CHROMIUM </span>administered intravenously to TPN patients has been shown to be nontoxic when given at dosage levels of up to 250 mcg/day for two consecutive weeks.</p>
<p>Reported toxic reactions to chromium include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and gastrointestinal tract, renal and <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatic damage</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. The acute LD<span class="Sub">50</span> for intravenous trivalent chromium was reported as 10 to 18 mg/kg.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_cd6f50f7-89dc-475e-a2e1-ca4898d8e9e1"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION
</span></h1>
<p class="First">The suggested dosage ranges for the four trace elements in neonates and pediatric patients are:</p>
<p>ZINC:			For full term infants and children up to 5 years of age, 100 mcg 				zinc/kg/day is recommended. For premature infants up to 3 kg in 				body weight, 300 mcg zinc/kg/day is suggested.</p>
<p>COPPER: 		For pediatric patients, the suggested additive dosage level is 20 				mcg copper/kg/day.</p>
<p>MANGANESE: 	For pediatric patients, a dosage of 2 to 10 mcg manganese/kg/day				is suggested.</p>
<p>CHROMIUM: 	For pediatric patients, the suggested additive dosage 0.14 to 0.20 				mcg chromium/kg/day.</p>
<p>Periodic monitoring of plasma levels of Zinc, Copper, Manganese and Chromium is suggested as a guideline preparation.</p>
<p>Aseptic addition of <span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 NEONATAL </span>to the TPN solution under a laminar flow hood is recommended. The trace elements present in the Neonatal Formula are physically compatible with the electrolytes and vitamins usually present in the amino acid/dextrose solution used for TPN.</p>
<p>Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_50a37422-51a7-4f8c-925c-369b9c0bb3c4"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED </span></h1>
<p class="First"><span class="Bold">MULTITRACE</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> - 4 NEONATAL (TRACE ELEMENTS INJECTION 4, USP)</span></p>
<p>NDC 0517-6202-25             2 mL Single Dose Vial           Packaged in boxes of 25</p>
<p>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).</p>
<p><span class="Bold">AMERICAN</span><span class="Bold"><br></span><span class="Bold">REGENT, INC.</span><span class="Bold"><br></span><span class="Bold">SHIRLEY, NY 11967</span></p>
<p>IN6202<br>Rev. 1/09</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_49c7a24b-f082-453a-b4eb-3344ca560593"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL </span></h1>
<p class="First"><span class="Underline">Container<br></span><span class="Bold"><br>NDC 0517-6202-25</span></p>
<p><span class="Bold">MULTITRACE<span class="Sup">®</span>-4 NEONATAL<br>(TRACE ELEMENTS INJECTION 4, USP)</span></p>
<p><span class="Bold">2 mL</span> SINGLE DOSE VIAL</p>
<p>FOR IV USE AFTER DILUTION</p>
<p><span class="Bold">Rx Only<br><br></span><span class="Bold">AMERICAN REGENT, INC.</span><br>SHIRLEY, NY  11967</p>
<div class="Figure"><img alt="Container" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68fdf062-4c4d-4533-9086-8976dd4ce5e1&amp;name=multitrace-4-neonatal-1.jpg"></div>
<p><span class="Underline">Carton<br><br></span><span class="Bold">MULTITRACE<span class="Sup">®</span>-4 NEONATAL<br>(TRACE ELEMENTS INJECTION 4, USP)</span></p>
<p><span class="Bold">NDC 0517-6202-25</span></p>
<p><span class="Bold">25 X 2 mL SINGLE DOSE VIALS</span></p>
<p><span class="Bold">FOR IV USE AFTER DILUTION - PRESERVATIVE FREE</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Each mL provides: Zinc 1.5 mg, Copper 0.1 mg, Manganese 25 mcg and Chromium 0.85 mcg. Each mL contains: Zinc Sulfate Heptahydrate) 6.6 mg, Cupric Sulfate (Pentahydrate) 0.39 mg, Manganese Sulfate (Monohydrate) 77 mcg, Chromic Chloride (Hexahydrate) 4.36 mcg, and Water for Injection q.s. pH may be adjusted with Sulfuric Acid and/or Sodium Hydroxide. Sterile, nonpyrogenic.<br><span class="Bold">WARNING</span>: DISCARD UNUSED PORTION - USE ONLY IF SOLUTION IS CLEAR.<br>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F); (See USP Controlled Room Temperature).<br>Directions for Use: See Package Insert.</p>
<p><span class="Bold">AMERICAN<br>REGENT, INC.</span><br>SHIRLEY, NY 11967</p>
<p>Rev. 11/05</p>
<div class="Figure"><img alt="Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68fdf062-4c4d-4533-9086-8976dd4ce5e1&amp;name=multitrace-4-neonatal-2.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MULTITRACE-4 NEONATAL 		
					</strong><br><span class="contentTableReg">trace elements 4 injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0517-6202</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ZINC SULFATE HEPTAHYDRATE</strong> (ZINC CATION) </td>
<td class="formItem">ZINC CATION</td>
<td class="formItem">6.6 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CUPRIC SULFATE</strong> (CUPRIC CATION) </td>
<td class="formItem">CUPRIC CATION</td>
<td class="formItem">0.39 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MANGANESE SULFATE</strong> (MANGANESE CATION (2+)) </td>
<td class="formItem">MANGANESE CATION (2+)</td>
<td class="formItem">77 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CHROMIC CHLORIDE</strong> (CHROMIC CATION) </td>
<td class="formItem">CHROMIC CATION</td>
<td class="formItem">4.36 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SULFURIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0517-6202-25</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">UNAPPROVED DRUG OTHER</td>
<td class="formItem"></td>
<td class="formItem">09/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>American Regent, Inc.
							(622781813)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Luitpold Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">002033710</td>
<td class="formItem">ANALYSIS(0517-6202), MANUFACTURE(0517-6202), STERILIZE(0517-6202)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c8aa6a43-0e1f-43e5-a042-e3b3a3e931dd</div>
<div>Set id: 68fdf062-4c4d-4533-9086-8976dd4ce5e1</div>
<div>Version: 3</div>
<div>Effective Time: 20140829</div>
</div>
</div> <div class="DistributorName">American Regent, Inc.</div></p>
</body></html>
